2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Phase 1
1
Status
Terminated
2
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
2
Sponsor
Cancer Type
Tumor-Agnostic
27
Gastrointestinal
12
Breast
10
Thoracic
7
Other hematologic neoplasm
4
Head & Neck
4
Myeloid
3
Lymphoid
3
Sarcoma
2
Gynecologic
2
Dermatologic
2
CNS
2
Plasma cell
1
Other solid neoplasm
1
Genitourinary
1
Endocrine
1
Classical hematology
1
Conditions
Brain Neoplasms
2313
Glioblastoma
2016
Glioma
1402
Central Nervous System Neoplasms
692
Astrocytoma
668
Neuroblastoma
647
Gliosarcoma
480
Oligodendroglioma
405
Neoplasms
405
Breast Neoplasms
327
Medulloblastoma
307
Carcinoma, Non-Small-Cell Lung
256
Meningioma
229
Recurrence
224
Sarcoma
215
Melanoma
207
Neoplasm Metastasis
202
Ependymoma
200
Lung Neoplasms
199
Neurofibromatosis 1
169
Lymphoma
162
Meningeal Carcinomatosis
138
Osteosarcoma
135
Ovarian Neoplasms
132
Wilms Tumor
123
Precursor Cell Lymphoblastic Leukemia-Lymphoma
123
Head and Neck Neoplasms
117
Lymphoma, Non-Hodgkin
116
Diffuse Intrinsic Pontine Glioma
113
Rhabdomyosarcoma
107
Interventions
Temozolomide
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Neoplasms, Second Primary
×
CNS
×
Clear all
NCT00638963
2017-06-14
STOP
Merck Sharp & Dohme LLC
Phase 2
Terminated
6 enrolled
9 charts
NCT00629187
2012-04-27
CN-306
Tufts Medical Center
Phase 1
Terminated
2 enrolled